Palbociclib for advanced or metastatic, oestrogen-receptor positive, HER2-negative, recurrent breast cancer – second line
NIHR HSRIC
Record ID 32016000357
English
Authors' objectives:
(ER) positive, HER2-negative breast cancer that has recurred following treatment with endocrine therapy. If licensed, palbociclib will offer an additional oral treatment option for this patient group. Palbociclib is a selective, small molecule inhibitor of cyclin-dependent kinases 4 and 6. Palbociclib does not currently have Marketing Authorisation in the EU for any indication.
Breast cancer is the most common cancer in the UK, accounting for 30% of all cancers in women. In 2012, there were 42,773 new cases of breast cancer in England. Breast cancer risk is strongly related to age, with 81% of cases occurring in women aged over 50 years. Approximately 5% of patients present with metastatic breast cancer, and around 30% of patients who present with localised disease will later develop metastases.
Current treatment options for women with advanced ER-positive and HER2-negative disease include endocrine therapies (including tamoxifen, luteinising hormone releasing hormones, fulvestrant, everolimus), chemotherapy (including anthracycline-, taxane-, or platinum-based regimens), surgery and radiotherapy. Palbociclib has recently completed a phase III clinical trial comparing its effect on progression-free survival against treatment with placebo. The trial is expected to report in June 2015.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/palbociclib-for-advanced-or-metastatic-oestrogen-receptor-positive-her2-negative-recurrent-breast-cancer-second-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Breast Neoplasms
- Estrogens
- Neoplasm Recurrence, Local
- Piperazines
- Pyridines
- Receptors, Estrogen
- Protein Kinase Inhibitors
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.